(WASHINGTON, D.C.) — Along with other key leaders in drug policy and research, including NIDA Director Dr. Nora Volkow, FDA Deputy Director Doug Throckmorton, and DEA Deputy Assistant Administrator Joseph Rannazzisi, SAM President Dr. Kevin Sabet was invited to give oral and written testimony to the U.S. Senate Caucus on International Narcotics Control this morning on the potential pitfalls and promise of CBD. The hearing is taking place now at the Dirksen Office Building, and Dr. Sabet’s written testimony can be found here; his oral remarks are here.
Sabet will testify, “Right now the current situation can be summed up this way: Most CBD manufacturers get away with selling whatever they say is CBD; researchers and other groups who want to follow the FDA/DEA rules are being stifled by bureaucracy; parents are left confused and frustrated; FDA approved CBD products could very well be held up through a lengthy DEA scheduling process; and state elected officials with absolutely no background in these issues are hastily putting laws together in the absence of robust federal action. This must change.”
Dr. Sabet went on to highlight SAM’s recent research report, as well as the health concerns brought about by an unregulated medical marijuana market. “With the exception of the very recent past, most medical marijuana companies have been able to conduct business unobstructed.”